Met Life Investment Management, LLC Janux Therapeutics, Inc. Transaction History
Met Life Investment Management, LLC
- $16.6 Billion
- Q2 2024
A detailed history of Met Life Investment Management, LLC transactions in Janux Therapeutics, Inc. stock. As of the latest transaction made, Met Life Investment Management, LLC holds 16,349 shares of JANX stock, worth $756,141. This represents 0.0% of its overall portfolio holdings.
Number of Shares
16,349
Previous 9,061
80.43%
Holding current value
$756,141
Previous $341,000
100.59%
% of portfolio
0.0%
Previous 0.0%
Shares
12 transactions
Others Institutions Holding JANX
# of Institutions
161Shares Held
36.8MCall Options Held
72.2KPut Options Held
103K-
Ra Capital Management, L.P. Boston, MA9.17MShares$424 Million5.79% of portfolio
-
Orbimed Advisors LLC San Diego, CA2.98MShares$138 Million3.01% of portfolio
-
Black Rock Inc. New York, NY2.34MShares$108 Million0.0% of portfolio
-
Adage Capital Partners Gp, L.L.C. Boston, MA2.33MShares$108 Million0.19% of portfolio
-
Janus Henderson Group PLC London, X01.8MShares$83.3 Million0.04% of portfolio
About Janux Therapeutics, Inc.
- Ticker JANX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 41,663,000
- Market Cap $1.93B
- Description
- Janux Therapeutics, Inc., a biopharmaceutical company, develops therapeutics based on proprietary Tumor Activated T Cell Engager (TRACTr) platform technology to treat patients suffering from cancer. The company's lead TRACTr product candidates that are in preclinical or discovery stage target prostate-specific membrane antigen, epidermal growth ...